TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8918026

Group type: EXPERIMENTAL
Intervention: 1% plain lidocaine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.25% plain bupivacaine (Marcaine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50/50 mixture of 1% lidocaine and 0.25% bupivacaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 12
Study: 1885426

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times daily for five days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily for five days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg twice a day for five days
Number of subjects: 54
Study: 6357901

Group type: EXPERIMENTAL
Intervention: Xenon-arc photocoagulation treatment in one eye
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (untreated eye)
Number of subjects: 99
Study: 30774040

Group type: EXPERIMENTAL
Intervention: Narrative message
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 378

Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 378
Study: 28912163

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Face mask (FM)
Number of subjects: 49
Study: 26936623

Group type: EXPERIMENTAL
Intervention: On-site bundled rapid HIV/HCV testing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25525349

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) plus carer training
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST) only
Number of subjects: 68

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 68
Study: 21681516

Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg once daily, orally)
Number of subjects: 168
Study: 19349517

Group type: COMPARATOR
Intervention: Nikkomycin Z 250 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nikkomycin Z 1,000 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nikkomycin Z 1,500 mg to 2,000 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nikkomycin Z (all doses)
Number of subjects: 12
Study: 17484872

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b/ribavirin for 48 weeks (group B)
Number of subjects: 81

Group type: COMPARATOR
Intervention: no treatment (group A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: severe recurrence treatment (group C)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: treatment (overall)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: treated patients (overall)
Number of subjects: 81
Study: 15139869

Group type: EXPERIMENTAL
Intervention: Matrix Model (manualized 16-week treatment)
Number of subjects: 978

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Matrix Model
Number of subjects: 978
Study: 11782895

Group type: EXPERIMENTAL
Intervention: Micronized diosmin (Daflon 500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonmicronized diosmin
Number of subjects: 12
Study: 9824860

Group type: EXPERIMENTAL
Intervention: Reversed Tip and Snip technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Divide and Conquer technique
Number of subjects: 60
Study: 7854294

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no NNS)
Number of subjects: 12
Study: 2065410

Group type: EXPERIMENTAL
Intervention: Scopolamine patch (0.75 mg or 0.375 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no patch)
Number of subjects: 50
Study: 7073303

Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim-sulphamethoxazole
Number of subjects: 42

Group type: COMPARATOR
Intervention: 7-day course of trimethoprim-sulphamethoxazole
Number of subjects: 42
Study: 31036580

Group type: EXPERIMENTAL
Intervention: Ace‐ER 6 g/d
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 28527855

Group type: EXPERIMENTAL
Intervention: XR-NTX treatment prior to release
Number of subjects: 15

Group type: COMPARATOR
Intervention: Post-release XR-NTX treatment
Number of subjects: 15
Study: 26044070

Group type: EXPERIMENTAL
Intervention: bapineuzumab 0.15 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: bapineuzumab 0.5 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: bapineuzumab 1.0 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: bapineuzumab 2.0 mg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 25104109

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1199
Study: 22196270

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0
Study: 18985345

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.3 mg/kg i.v.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 24
Study: 17901415

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 15682684

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) treatment (2.8 atmospheres absolute, 100 minutes, three treatments within the first 24 hours)
Number of subjects: 8
Study: 12195070

Group type: EXPERIMENTAL
Intervention: Variable-angle Roman chair exercise group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no resistance exercise)
Number of subjects: 36
Study: 9665078

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZI)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8080233

Group type: EXPERIMENTAL
Intervention: Mebendazole 500 mg single dose
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study: 2635255

Group type: EXPERIMENTAL
Intervention: diltiazem 120 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 31889382

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: IPL
Number of subjects: 30
Study: 31113728

Group type: EXPERIMENTAL
Intervention: FFRCT ≤0.80
Number of subjects: 68

Group type: COMPARATOR
Intervention: FFRCT >0.80
Number of subjects: 68
Study: 29191585

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel (10mg/kg and 75mg/m2 respectively)
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 1253
Study: 26110437

Group type: EXPERIMENTAL
Intervention: Flavanol-rich beverage
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22910100

Group type: EXPERIMENTAL
Intervention: Light-exposed group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dark-exposed group
Number of subjects: 16
Study: 22436478

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 0
Study: 19474823

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17209722

Group type: EXPERIMENTAL
Intervention: Journey of Hope (JOH) education course
Number of subjects: 462

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 462
Study: 12630999

Group type: EXPERIMENTAL
Intervention: Precautionary positioning group (n = 59)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Non-precautionary positioning group (n = 48)
Number of subjects: 107
Study: 10671339

Group type: EXPERIMENTAL
Intervention: Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Number of subjects: 117
Study: 9328492

Group type: EXPERIMENTAL
Intervention: Intensive psychosocial treatment
Number of subjects: 274

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 274
Study: 8473584

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment (CBT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 56
Study: 3810052

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31603013

Group type: EXPERIMENTAL
Intervention: Circadian lighting environment (intervention group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Lighting as usual (control group)
Number of subjects: 54
Study: 30203758

Group type: EXPERIMENTAL
Intervention: Lamivudine in addition to conventional Anti-TB therapy and liver-protecting therapy
Number of subjects: 4200

Group type: COMPARATOR
Intervention: Conventional Anti-TB therapy and liver-protecting therapy
Number of subjects: 4200
Study: 27638993

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Number of subjects: 20
Study: 24809770

Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation (seawater)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intranasal corticosteroids (INS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined treatment (nasal saline irrigation + INS)
Number of subjects: 61
Study: 22901955

Group type: EXPERIMENTAL
Intervention: STRETCH programme (educational outreach training of nurses to initiate and represcribe ART)
Number of subjects: 12282

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 12282
Study: 20536619

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of <150 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systolic blood pressure target of <180 mmHg
Number of subjects: 0
Study: 18412995

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and other antioxidants in foods (large doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet rich in fruit and vegetables
Number of subjects: 0
Study: 15910137

Group type: EXPERIMENTAL
Intervention: Backward associative strength (BAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forward associative strength (FAS)
Number of subjects: 0
Study: 12145999

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Exemestane 50 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: Exemestane 25 mg (crossover study)
Number of subjects: 4
Study: 10538330

Group type: EXPERIMENTAL
Intervention: Model for estimating medical costs based on variables such as length of stay, nursing workload, severity of condition, and procedures recorded.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Validation of the cost model using a second sample of 29 patients.
Number of subjects: 102
Study: 8679024

Group type: EXPERIMENTAL
Intervention: Group I: 50 mg of 0.25% bupivacaine and 1 mg of morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group II: 50 mg of 0.25% bupivacaine and 100 micrograms of fentanyl
Number of subjects: 30
Study: 1827107

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg (2 x 125 mg capsules) 12-hourly
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ampicillin 250 mg (one capsule) 6-hourly
Number of subjects: 225
Study: 7020820

Group type: EXPERIMENTAL
Intervention: co‐trimoxazole
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: cephalexin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: carfecillin
Number of subjects: 200

Group type: COMPARATOR
Intervention: control
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: all 3 antibiotics
Number of subjects: 200
Study: 30677646

Group type: EXPERIMENTAL
Intervention: Pharmacogenomics-guided intervention arm (guided-care)
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Congruent medications after switching from incongruent medications
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Incongruent medications
Number of subjects: 1167
Study: 28112981

Group type: EXPERIMENTAL
Intervention: Oral porcine placental extract (PPE) 300 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25070148

Group type: EXPERIMENTAL
Intervention: FDC of Soli 6 mg plus TOCAS 0.4 mg
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: FDC of Soli 9 mg plus TOCAS 0.4 mg
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: FDC of Soli 6 mg plus TOCAS 0.4 mg or Soli 9 mg plus TOCAS 0.4 mg
Number of subjects: 1066
Study: 23292744

Group type: EXPERIMENTAL
Intervention: PCOS group (19 subjects)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-PCOS group (21 subjects)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MRI imaging at 2 mm slice thickness
Number of subjects: 40
Study: 20399146

Group type: EXPERIMENTAL
Intervention: Combination of imipramine with pseudoephedrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Imipramine with placebo
Number of subjects: 100
Study: 19196111

Group type: EXPERIMENTAL
Intervention: SRP + LAS
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: LAS alone
Number of subjects: 30
Study: 17571256

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 50 mg
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Dipyrone 2 g
Number of subjects: 308
Study: 15669707

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 11
Study: 12477522

Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 30

Group type: COMPARATOR
Intervention: recombinant human LH
Number of subjects: 30
Study: 9811984

Group type: EXPERIMENTAL
Intervention: OPLL patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 7633015

Group type: EXPERIMENTAL
Intervention: Clinafloxacin 200 mg iv q12h
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Theophylline 300 mg tid (initially) then reduced to 200 mg tid after toxicity was observed
Number of subjects: 1

Group type: COMPARATOR
Intervention: Theophylline 400 mg bid (initially)
Number of subjects: 1
Study: 2199211

Group type: EXPERIMENTAL
Intervention: Chlorbutol (2.5 mg.ml-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methacholine (0.13-4.0 mg.ml-1)
Number of subjects: 10
Study: 845912

Group type: EXPERIMENTAL
Intervention: Feedback of simple ambulatory practice profiles
Number of subjects: 21

Group type: COMPARATOR
Intervention: No feedback of profiles (Control)
Number of subjects: 21
Study: 31034594

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) and physical therapy (PT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study: 28383379

Group type: EXPERIMENTAL
Intervention: pH‐balanced vaginal gel containing lactic acid
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (lactate‐free gel)
Number of subjects: 136
Study: 26307181

Group type: EXPERIMENTAL
Intervention: Moleca(®) footwear (worn for at least 6h/day, 7 days/week, over 6 months)
Number of subjects: 56
Study: 23768792

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 121

Group type: COMPARATOR
Intervention: High ligation and stripping
Number of subjects: 121
Study: 21112360

Group type: EXPERIMENTAL
Intervention: Buffet lunches (pizza/tacos/sub sandwiches with salad bar and choice of beverage and dessert)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control lunch (ad libitum, fixed-item lunch)
Number of subjects: 32
Study: 19559137

Group type: EXPERIMENTAL
Intervention: Diet restricted in fermentable, poorly absorbed carbohydrates (including fructose, fructans, sorbitol, and other sugar alcohols)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased intake of soluble fiber
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily use of peppermint oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fiber (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics (live-culture yogurt and buttermilk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified exclusion diet and stepwise reintroduction of foods
Number of subjects: 0
Study: 16751757

Group type: EXPERIMENTAL
Intervention: Controlled bipolar conjunctival cautery
Number of subjects: 144
Study: 15134307

Group type: EXPERIMENTAL
Intervention: Children with catch-up growth
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Children without catch-up growth
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Children followed longitudinally for 1 year
Number of subjects: 60

Group type: COMPARATOR
Intervention: Socio-economic status
Number of subjects: 60
Study: 11501507

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(-1) ointment (Silkis ointment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitriol 15 microg g(-1) ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 0
Study: 9375952

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL (12.5 mg or 25 mg once daily, titrated to 200 mg)
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3200
Study: 8352424

Group type: EXPERIMENTAL
Intervention: Washed shed blood
Number of subjects: 26

Group type: COMPARATOR
Intervention: Unwashed shed blood
Number of subjects: 26
Study: 3112727

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 21

Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 21
Study: 30015637

Group type: EXPERIMENTAL
Intervention: 5-minute physical exertion protocol
Number of subjects: 87

Group type: COMPARATOR
Intervention: at rest
Number of subjects: 87
Study: 29298678

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Physical training (exergaming)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 150
Study: 27192969

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 670

Group type: COMPARATOR
Intervention: Dasatinib (other dose groups)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Dasatinib (all doses)
Number of subjects: 670
Study: 26715519

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block with 0.33% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous tramadol 1.5 mg/kg
Number of subjects: 60
Study: 24324377

Group type: EXPERIMENTAL
Intervention: Postoperative corticosteroid administration (PCA group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 39
Study: 20570883

Group type: EXPERIMENTAL
Intervention: High EGFR expression (assessed by immunohistochemistry) in 103 out of 145 OPLs (71%)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: FISH-positive lesions (increased EGFR gene copy number) in 20 out of 49 OPLs (41%)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: FISH-positive group
Number of subjects: 162
Study: 18954355

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel administered topically every 24 h for 6 consecutive days
Number of subjects: 35

Group type: COMPARATOR
Intervention: 1.23% sodium fluoride gel administered topically every 24 h for 6 consecutive days
Number of subjects: 35
Study: 16176154

Group type: EXPERIMENTAL
Intervention: CoQ10 Q-Gel Softsules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CoQ10 all-Q
Number of subjects: 12

Group type: COMPARATOR
Intervention: CoQ10 Q-SorB
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CoQ10 all-Q and Q-Gel
Number of subjects: 12
Study: 12803737

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg (increased to 60 mg if necessary)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg (increased to 10 mg if necessary)
Number of subjects: 155
Study: 10795650

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 200 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mometasone furoate dry powder inhaler (MF DPI) 400 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8969284

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 49
Study: 1507019

Group type: EXPERIMENTAL
Intervention: Therapies evaluated based on actual clinical changes rather than presumed etiologic factors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies to correlate events observed at sites within the dentition.
Number of subjects: 0
Study: 6484553

Group type: EXPERIMENTAL
Intervention: Amoxycillin 3 g
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin 1.5 g and 0.5 g (6 h apart)
Number of subjects: 12
Study: 30185793

Group type: EXPERIMENTAL
Intervention: THC 8 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CBD 16 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: THC 8 mg + CBD 16 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26948254

Group type: EXPERIMENTAL
Intervention: No GRV monitoring (n = 26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: GRV monitoring (n = 25)
Number of subjects: 51
Study: 24597866

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 695

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 695
Study: 22266974

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP) treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 40
Study: 20617289

Group type: EXPERIMENTAL
Intervention: Intensive weight loss (WL) group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Weight stable (WS) control group
Number of subjects: 71
Study: 18945240

Group type: COMPARATOR
Intervention: IV morphine sulfate 0.1 mg/kg
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Oral oxycodone 0.125 mg/kg
Number of subjects: 328
Study: 15823446

Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF) challenge
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lyso-PAF (L-PAF) challenge
Number of subjects: 12